NCT04106700 is a Phase 2 clinical trial of Apixaban 2.5 MG in Venous Thromboembolism, sponsored by Instituto de Investigacion Sanitaria La Fe.

Who is sponsoring NCT04106700?

NCT04106700 is sponsored by Instituto de Investigacion Sanitaria La Fe.

What drugs are being tested in NCT04106700?

Interventions in NCT04106700: Apixaban 2.5 MG.

What condition does NCT04106700 study?

NCT04106700 studies Venous Thromboembolism.

Is NCT04106700 still recruiting?

NCT04106700 is currently terminated. Last updated 15 February 2021.

Last reviewed 2021-02-15 · How we verify

NCT04106700

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDs

Terminated Phase 2 Last updated 15 February 2021

What this trial tests

Phase 2 trial testing Apixaban 2.5 MG in Venous Thromboembolism in 60 participants. Terminated before completion.

Timeline

12 April 2019

Primary endpoint
26 August 2020

5 October 2020

Quick facts

Lead sponsor	Instituto de Investigacion Sanitaria La Fe
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	12 April 2019
Primary completion	26 August 2020
Estimated completion	5 October 2020
Sites	4 locations across Spain

Drugs / interventions tested

Apixaban 2.5 MG — full drug profile →

Conditions studied

Venous Thromboembolism — all drugs for Venous Thromboembolism →

Sponsor

Instituto de Investigacion Sanitaria La Fe — full company profile →

Who can join

Adults 18 to 70, any sex, with Venous Thromboembolism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Interventional, no-randomized, open-label, and single arm multicentre study of apixaban for the prevention of thromboembolic events during induction therapy in transplant-eligible patients with newly diagnosed multiple myeloma who receive bortezomib, thalidomide, and dexamethasone (VTD) during the induction phase of therapy prior to autologous stem cell transplantation (ASCT). The current study is designed to evaluate the efficacy and safety of apixaban during the induction period. Efficacy will be defined as a composite endpoint of acute symptomatic proximal and distal deep venous thrombosis, pulmonary embolism, VTE related deaths, and acute ischemic stroke.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Rutjes AW, Porreca E, Candeloro M, Valeriani E, et al · · 2020 · cited 29× · PMID 33337539 · DOI 10.1002/14651858.cd008500.pub5

Verify or expand the search:

Other trials of Apixaban 2.5 MG

Trials testing the same drug.

NCT07461532 — Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD · NA · recruiting
NCT07461545 — Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS · NA · recruiting
NCT06523959 — Avoiding Risks of Thrombosis and Bleeding in Surgery (ARTS) Trial · Phase 4 · recruiting
NCT05304455 — Apixaban Prevents Portal Vein Thrombosis After Laparoscopic Splenectomy and Azygoportal Disconnection · NA · completed
NCT04746339 — Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19 · Phase 4 · terminated

Other recruiting trials for Venous Thromboembolism

Currently open trials in the same condition.

NCT07399977 — Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism · NA · recruiting
NCT06861088 — The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer · Phase 3 · recruiting
NCT07140523 — A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA · Phase 2 · recruiting
NCT04211181 — CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism · NA · recruiting
NCT06440694 — Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The Conquer-DVT Pilot Trial) · Phase 3 · recruiting

Other Instituto de Investigacion Sanitaria La Fe trials

Trials by the same sponsor.

NCT07402083 — Administration of Extracellular Vesicles From Donor Human Milk in Preterm Infants · recruiting
NCT07238608 — Impact of UFPs and MNPs on Fetal Health · recruiting
NCT06950996 — A Clinical Evaluation of AI Solutions Developed in the CHAIMELEON Project for Cancer: Prostate, Lung, Breast, Colon and · completed
NCT06866769 — Efficacy of Biomarkers and CEUS Versus CTA in AAA Follow-up Post-EVAR · recruiting
NCT07478445 — Home Rehabilitation After Hip Fracture · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04106700 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Instituto de Investigacion Sanitaria La Fe
Last refreshed: 15 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04106700.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing